Changing paradigms of health care and increasing knowledge of opioid addiction continue to influence the attitudes of the health profession toward methadone maintenance treatment (MMT). This approach has again reached the forefront of attention because of its significant role in reducing HIV transmission associated with intravenous drug use. In spite of the well-documented benefits of MMT, patients continue to detoxify from methadone for a variety of reasons both overt and covert. Variable outcomes and generally poor long-term abstinence rates results. At present uncertainty still exists surrounding who should attempt detoxification, when or how this should be done, or whether in fact detoxification should be attempted at all. This article describes and examines factors that are positively and negatively associated with detoxification outcome. Evidence for the interrelationship of two notably significant determinants, affective states and protracted withdrawal, are presented and discussed as they relate to theories of relapse and outcome.

Methadone maintenance treatment (MMT) for opioid dependency has consistently shown important heath, social and legal benefits. What started as a small experimental program in Lexington, Kentucky has grown and expanded substantially over 35 years. Its practice is now well established both in specialized centers and in the broader community. In society, methadone deaths represent an important issue of public safety: methadone diversion to and ingestion by nontolerant individuals outside of treatment. Within treatment, methadone deaths occur most commonly in the early stabilization period (due to issue of tolerance), in periods of transition, or among certain individuals who abuse other substances (opioids, benzodiazepines, or alcohol). Research suggests moderately high methadone dosages help improve patient retention. Results from pharmacodynamic, kinetic and stereospecific studies continue to support the importance of individualizing dose. For some patients, much larger doses may be necessary to fully achieve all pharmacotherapy goals of treatment. Practitioners must be cautious however as certain patients on higher dosages are predisposed to torsade de pointes and increased mortality. Policymakers have a responsibility in their decision-making to balance the quality of life benefits for patients within MMT with the risks of increased mortality both for individuals within treatment and the general public.

No abstract

No abstract

No abstract